R01 CA143126/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2010	1
2011	3
2012	5
2013	8
2014	2
2015	6
2016	4
2017	1
2018	1
2024	0

1

Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?

Williams MM, Cook RS. Williams MM, et al. Oncotarget. 2015 Feb 28;6(6):3519-30. doi: 10.18632/oncotarget.2792. Oncotarget. 2015. PMID: 25784482 Free PMC article. Review.

2

Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program.

Pulley JM, Jerome RN, Ogletree ML, Bernard GR, Lavieri RR, Zaleski NM, Hong CC, Shirey-Rice JK, Arteaga CL, Mayer IA, Holroyd KJ, Cook RS. Pulley JM, et al. Target Oncol. 2018 Feb;13(1):61-68. doi: 10.1007/s11523-017-0542-1. Target Oncol. 2018. PMID: 29218624 Free PMC article. Review.

3

Mouse Models of Breast Cancer: Platforms for Discovering Precision Imaging Diagnostics and Future Cancer Medicine.

Manning HC, Buck JR, Cook RS. Manning HC, et al. J Nucl Med. 2016 Feb;57 Suppl 1(Suppl 1):60S-8S. doi: 10.2967/jnumed.115.157917. J Nucl Med. 2016. PMID: 26834104 Free PMC article. Review.

4

mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis.

Morrison MM, Young CD, Wang S, Sobolik T, Sanchez VM, Hicks DJ, Cook RS, Brantley-Sieders DM. Morrison MM, et al. PLoS Genet. 2015 Jul 1;11(7):e1005291. doi: 10.1371/journal.pgen.1005291. eCollection 2015 Jul. PLoS Genet. 2015. PMID: 26132202 Free PMC article.

5

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.

Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL. Bhola NE, et al. J Clin Invest. 2013 Mar;123(3):1348-58. doi: 10.1172/JCI65416. Epub 2013 Feb 8. J Clin Invest. 2013. PMID: 23391723 Free PMC article.

6

Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.

Morrison Joly M, Hicks DJ, Jones B, Sanchez V, Estrada MV, Young C, Williams M, Rexer BN, Sarbassov dos D, Muller WJ, Brantley-Sieders D, Cook RS. Morrison Joly M, et al. Cancer Res. 2016 Aug 15;76(16):4752-64. doi: 10.1158/0008-5472.CAN-15-3393. Epub 2016 Apr 25. Cancer Res. 2016. PMID: 27197158 Free PMC article.

7

Efferocytosis creates a tumor microenvironment supportive of tumor survival and metastasis.

Vaught DB, Stanford JC, Cook RS. Vaught DB, et al. Cancer Cell Microenviron. 2015;2(1):e666. doi: 10.14800/ccm.666. Cancer Cell Microenviron. 2015. PMID: 29264372 Free PMC article.

8

Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.

Williams MM, Lee L, Hicks DJ, Joly MM, Elion D, Rahman B, McKernan C, Sanchez V, Balko JM, Stricker T, Estrada MV, Cook RS. Williams MM, et al. Mol Cancer Res. 2017 Mar;15(3):259-268. doi: 10.1158/1541-7786.MCR-16-0280-T. Epub 2016 Dec 30. Mol Cancer Res. 2017. PMID: 28039357 Free PMC article.

9

Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.

Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL. Garrett JT, et al. Clin Cancer Res. 2013 Feb 1;19(3):610-9. doi: 10.1158/1078-0432.CCR-12-2024. Epub 2012 Dec 5. Clin Cancer Res. 2013. PMID: 23224399 Free PMC article.

10

Cooperative signaling between Slit2 and Ephrin-A1 regulates a balance between angiogenesis and angiostasis.

Dunaway CM, Hwang Y, Lindsley CW, Cook RS, Wu JY, Boothby M, Chen J, Brantley-Sieders DM. Dunaway CM, et al. Mol Cell Biol. 2011 Feb;31(3):404-16. doi: 10.1128/MCB.00667-10. Epub 2010 Dec 6. Mol Cell Biol. 2011. PMID: 21135133 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

25 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year